NDT Advance Access originally published online on April 26, 2005
Nephrology Dialysis Transplantation 2005 20(8):1582-1591; doi:10.1093/ndt/gfh859
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction
Internal Medicine, Renal Division, University of São Paulo, São Paulo, Brazil
Correspondence and offprint requests to: José Mauro Vieira Jr, Internal Medicine, Renal Division, University of São Paulo, São Paulo, Brazil. Email: josemvjr{at}usp.br
Background. The pleiotropic actions of statins have been largely explored. These drugs have been tested in several models of progressive renal disease, most of them accompanied by hypertension. We sought to investigate more closely the effects of simvastatin on renal interstitial fibrosis due to unilateral ureteral obstruction (UUO).
Methods. Munich-Wistar rats were submitted to UUO and studied after 14 days. Animals were divided into two groups: vehicle (VH) or simvastatin (SIMV) 2 mg/kg b.i.d. by gavage. At sacrifice kidneys were harvested for morphology, mRNA and protein analysis. RT–PCR was done to assess expression of collagen I and III, fibronectin, MCP-1, TGF-ß1 and bFGF. Protein expression was assessed by western blot (TGF-ß) and immunostaining (macrophage, lymphocyte, PCNA, vimentin and 
-smooth muscle actin). Contralateral kidneys (CL) were used as controls.
Results. SIMV-treated animals had less severe renal inflammation. MCP-1 was markedly expressed in obstructed kidneys and diminished with SIMV (48.9± 2.5 vs 64.3±3.1 OD in VH, P<0.01). Interstitial fibrosis (IF) was significantly attenuated with SIMV (8.2±1.3 vs 13.2±0.6%, P<0.01 SIMV vs VH), which was confirmed by a decrease in collagen I and fibronectin renal expression. Vimentin, a marker of dedifferentiation, was expressed in tubular cells of VH and decreased with SIMV treatment. -SMA, a marker of myofibroblast-type cells, was increased in renal interstitium of VH rats and SIMV significantly reduced its expression. PCNA was increased in the UUO kidneys, but SIMV did not decrease tubular or interstitial proliferating cells. TGF-ß1, which was highly induced in the obstructed kidneys, decreased at the post-transcriptional level with SIMV treatment (5.35±0.75 vs 13.10±2.9 OD in VH, P<0.05). bFGF mRNA was also overexpressed in the obstructed kidneys, although SIMV treatment did not significantly decrease its expression.
Conclusions. SIMV had an evident protective effect on renal interstitial inflammation and fibrosis. It is conceivable that by attenuating inflammation, SIMV prevented tubular activation and transdifferentiation, two processes largely involved in the renal fibrosis of the UUO model.
Keywords: inflammation; interstitial fibrosis; MCP-1; simvastatin; transdifferentiation; unilateral ureteral obstruction
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K.-h. Cho, H.-j. Kim, B. Rodriguez-Iturbe, and N. D. Vaziri Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure Am J Physiol Renal Physiol, July 1, 2009; 297(1): F106 - F113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Van Beneden, L. A. van Grunsven, C. Geers, M. Pauwels, A. Desmouliere, D. Verbeelen, A. Geerts, and C. Van den Branden CRBP-I in the renal tubulointerstitial compartment of healthy rats and rats with renal fibrosis Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3464 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Meyer-ter-Vehn, B. Katzenberger, H. Han, F. Grehn, and G. Schlunck Lovastatin Inhibits TGF-{beta}-Induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3955 - 3960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Campese and J. Park HMG-CoA Reductase Inhibitors and Renal Function Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1100 - 1103. [Full Text] [PDF]
|
|